About IRASPEN
This registry is a multicenter, longitudinal study with prospective collection of data and biological material.
At least 10 sites worldwide will participate in the registry. We plan to enroll at least 150 patients in at least 10 countries. The duration of the registry is 5 years and will include 14 visits.
Each site will be asked to involve at least 20 patients.
Patients will be informed about the purpose of the registry at the dermatology departments of the participating sites and will be asked to give their informed consent to participate. For patients who have given informed consent, phenotypic description will be collected at baseline.
Phenotypic description
At baseline and at every following visit, the investigator will record a detailed phenotypic characterization of the patient’s clinical features. A case report form (Appendix 2) is going to be used, as well as a number of clinical scores (see below).
We Value Your Privacy!
We and our partners are using technologies like cookies and process personal data like the IP-address or browser information in order to analyze the website data. This helps us to improves your internet experience. We also use it in order to measure results or align our website content. Because we value your privacy, we are herewith asking for your permission to use these technologies. You can always change/withdraw your consent later.
Settings
Cookies